ArticleMedical oncology (Northwood, London, England)2025
NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering the malignant synergy: metabolic reprogramming, epigenetic circuitry, and niche remodeling in osteosarcoma-macrophage crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS), in which immune cells play an important role in the development and progression of OS, is the most common malignant bone tumor in the adolescent population. In this study, we performed bioconfidence analysis and experimental confirmation of the expression of the immune gene NFATC3 in OS and its function. qRT-PCR revealed high expression of NFATC3 in several OS cell lines, including 143B, SJSA, HOS, MG63, and MNNG, which was validated by multiple osteosarcoma sequencing datasets. MNNG overexpression of NFATC3 increased the proliferation and migration of MNNG cells. Single-cell sequencing analysis of the OS microenvironment revealed increased expression of NFATC3 in T cells and macrophages. Next, we further analyzed the expression of NFATC3 in the OS microenvironment using single cells. Finally, we explored the mechanism by which NFATC3 affects OS progression. Our results revealed that the overexpression of NFATC3 promoted the expression of PD-L1 ligands and the upregulation of inflammatory factors (IL-1β and TNF-α). The results from the construction of a tumor cell and macrophage coculture system revealed that the overexpression of NFATC3 promoted the expression of CXCL2 in M0 macrophages. In conclusion, our study suggests that NFATC3 drives the development of OS by promoting tumor cell proliferation and remodeling the immune microenvironment.
Indexed as
Identifiers
40728758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.